Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022919 | 0.92 | ABCC1 (0.54) | ACLYABCC1MAPTKDM4EALDH1A1 | |
| SCHEMBL22022935 | 0.92 | ACLY (0.57) | ACLYABCC1MAPTKDM4EALDH1A1 | |
| SCHEMBL22022920 | 0.90 | ACLY (0.54) | ACLYABCC1KDM4EALDH1A1PKM | |
| SCHEMBL22022879 | 0.89 | ACLY (0.49) | ACLYABCC1MAPTKDM4EALDH1A1 | |
| SCHEMBL22071200 | 0.89 | ACLY (0.55) | ACLYABCC1KDM4EALDH1A1PKM | |
| SCHEMBL22022876 | 0.87 | ACLY (0.51) | ACLYABCC1KDM4EALDH1A1PKM | |
| SCHEMBL22022878 | 0.87 | ACLY (0.60) | ACLYABCC1MAPTKDM4EALDH1A1 | |
| SCHEMBL22022925 | 0.84 | ACLY (0.50) | ACLYABCC1KDM4EALDH1A1PKM | |
| SCHEMBL22022885 | 0.83 | ACLY (0.64) | ACLYBCL2KDM4EALDH1A1HCAR2 | |
| SCHEMBL22022937 | 0.81 | HCAR2 (0.56) | ACLYABCC1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-02-24 | — | — | US | claimed |
| EP-3662908-A1 | MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-06-10 | — | — | EP | claimed |
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-02-24 | — | — | US | disclosed |
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3890734-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115019-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2020-06-11 | — | — | WO | disclosed |
| EP-3662908-A1 | MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-06-10 | — | — | EP | disclosed |
| EP-3662908-A1 | MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054438-A1 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | KCNK2, KCNT2, KCNT1 | ACLY 3559/4885ABCC1 588/4885BCL2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.